After integrative analysis, including comparison of functional protein–protein interactions and patient survival (PFS and OS) of serous ovarian carcinomas, we obtained four potentially important DEGs: SRC, ARNT, TBP, and SNAI2. Finally, IHC validation of these four biomarkers revealed that they significantly increased in samples incrementally from serous BOT to early stages and then to late stages of serous ovarian carcinomas. This evidence concerns the gene TBP and ovarian serous carcinoma.